MX2014010925A - Compuesto de heterociclilo. - Google Patents

Compuesto de heterociclilo.

Info

Publication number
MX2014010925A
MX2014010925A MX2014010925A MX2014010925A MX2014010925A MX 2014010925 A MX2014010925 A MX 2014010925A MX 2014010925 A MX2014010925 A MX 2014010925A MX 2014010925 A MX2014010925 A MX 2014010925A MX 2014010925 A MX2014010925 A MX 2014010925A
Authority
MX
Mexico
Prior art keywords
compounds
formula
present
heterocyclyl compounds
heteroaryl
Prior art date
Application number
MX2014010925A
Other languages
English (en)
Other versions
MX355526B (es
Inventor
Venkata P Palle
Rajender Kumar Kamboj
Bhavesh Dave
Rakesh Kumar Banerjee
Samiron Phukan
Abhijit Datta Khoje
Rajkumar Hangarge
Jitendra Sambhaji Jadhav
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014010925(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2014010925A publication Critical patent/MX2014010925A/es
Publication of MX355526B publication Critical patent/MX355526B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención se relaciona con compuestos de heteroarilo como inhibidores de MEK. La invención incluye compuestos de heteroarilo de fórmula I, sus tautómeros y sales farmacéuticamente aceptables, combinaciones con composiciones de medicamentos y farmacéuticas adecuadas de los mismos. La presente invención también incluye un proceso de preparación de dichos compuestos y su uso pretendido en terapia. (ver Fórmula).
MX2014010925A 2012-03-14 2013-03-11 Compuesto de heterociclilo. MX355526B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14
PCT/IB2013/051915 WO2013136254A1 (en) 2012-03-14 2013-03-11 Heterocyclyl compounds

Publications (2)

Publication Number Publication Date
MX2014010925A true MX2014010925A (es) 2015-04-10
MX355526B MX355526B (es) 2018-04-20

Family

ID=47997632

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014010925A MX355526B (es) 2012-03-14 2013-03-11 Compuesto de heterociclilo.
MX2014010928A MX355474B (es) 2012-03-14 2013-03-11 Compuestos de heterociclilo como inhibidores de mek.
MX2018003665A MX366426B (es) 2012-03-14 2013-03-11 Compuestos de heterociclilo como inhibidores de mek.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2014010928A MX355474B (es) 2012-03-14 2013-03-11 Compuestos de heterociclilo como inhibidores de mek.
MX2018003665A MX366426B (es) 2012-03-14 2013-03-11 Compuestos de heterociclilo como inhibidores de mek.

Country Status (36)

Country Link
US (5) US9428499B2 (es)
EP (2) EP2834237B1 (es)
JP (3) JP6093384B2 (es)
KR (4) KR102241111B1 (es)
CN (4) CN107698585A (es)
AP (2) AP3834A (es)
AU (4) AU2013234009B2 (es)
BR (1) BR112014022713B1 (es)
CA (2) CA2865167C (es)
CL (2) CL2014002411A1 (es)
CO (2) CO7160029A2 (es)
CR (2) CR20140463A (es)
CU (2) CU24335B1 (es)
DK (2) DK2834236T3 (es)
DO (2) DOP2014000203A (es)
EA (2) EA029768B1 (es)
ES (2) ES2741896T3 (es)
GE (2) GEP201706671B (es)
GT (2) GT201400195A (es)
HK (2) HK1202538A1 (es)
IL (2) IL234560A (es)
IN (2) IN2014MN01755A (es)
MA (2) MA37400B1 (es)
MX (3) MX355526B (es)
MY (2) MY175950A (es)
NI (2) NI201400108A (es)
NZ (2) NZ629432A (es)
PE (2) PE20141973A1 (es)
PH (2) PH12014502041A1 (es)
PL (1) PL2834237T3 (es)
SG (2) SG11201405007QA (es)
TN (2) TN2014000356A1 (es)
TR (1) TR201811976T4 (es)
UA (2) UA114906C2 (es)
WO (2) WO2013136249A1 (es)
ZA (1) ZA201406186B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
IN2014MN01755A (es) 2012-03-14 2015-07-03 Lupin Ltd
BR112014030812B1 (pt) 2012-06-13 2022-11-08 Incyte Holdings Corporation Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
RU2667892C2 (ru) 2013-10-25 2018-09-25 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Производные пиридилкетона, способ их получения и их фармацевтическое применение
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) * 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
AR114164A1 (es) 2017-12-21 2020-07-29 Boehringer Ingelheim Int Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
KR20210018265A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 고체 형태 및 이의 제조 방법
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
CA3142239A1 (en) 2019-06-19 2020-12-24 Boehringer Ingelheim International Gmbh Anticancer combination therapy
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114502169A (zh) * 2019-07-30 2022-05-13 埃德文斯公司 用于治疗中风的mek抑制剂
EP3797899A1 (de) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
JP2022552324A (ja) 2019-10-14 2022-12-15 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2023528623A (ja) 2020-06-02 2023-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
CN117479942A (zh) 2021-04-09 2024-01-30 勃林格殷格翰国际有限公司 抗癌疗法
KR20230172548A (ko) * 2021-04-16 2023-12-22 이케나 온콜로지, 인코포레이티드 Mek 억제제 및 이의 용도
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
WO2023099620A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
TW202337431A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
TW202337432A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099623A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
AU2003237009B2 (en) * 2002-01-22 2008-10-02 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3d]pyrimidin-7-ones
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
PT2251327E (pt) 2003-11-19 2014-03-04 Array Biopharma Inc Inibidores heterocíclicos de mek
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
ATE383360T1 (de) * 2004-06-11 2008-01-15 Japan Tobacco Inc 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h- pyrido(2,3-d)pyrimidinderivate und verwandte verbindungen zur behandlung von krebs
AU2009344690A1 (en) 2009-04-21 2011-10-27 Novartis Ag Heterocyclic compounds as MEK inhibitors
IN2014MN01755A (es) 2012-03-14 2015-07-03 Lupin Ltd

Also Published As

Publication number Publication date
BR112014022713B1 (pt) 2021-09-08
AP3859A (en) 2016-10-31
AU2013234009A1 (en) 2014-09-25
NZ629442A (en) 2016-12-23
CL2014002412A1 (es) 2015-03-06
AU2013234014B2 (en) 2017-02-02
JP2015514056A (ja) 2015-05-18
UA114907C2 (uk) 2017-08-28
CA2865167C (en) 2019-08-06
JP2018115215A (ja) 2018-07-26
NI201400107A (es) 2014-11-26
CO7160029A2 (es) 2015-01-15
EA201491672A1 (ru) 2014-12-30
US9555035B2 (en) 2017-01-31
EP2834237A1 (en) 2015-02-11
CL2014002411A1 (es) 2015-04-06
MY174188A (en) 2020-03-12
GT201400195A (es) 2017-11-09
TN2014000357A1 (en) 2015-12-21
JP6630771B2 (ja) 2020-01-15
US9428499B2 (en) 2016-08-30
KR102241111B1 (ko) 2021-04-15
ZA201406186B (en) 2016-06-29
CN107698585A (zh) 2018-02-16
MA37400A1 (fr) 2016-05-31
EP2834237B1 (en) 2018-06-06
KR102240101B1 (ko) 2021-04-14
CU20140109A7 (es) 2014-11-27
DOP2014000203A (es) 2015-02-15
PH12014502040A1 (en) 2014-11-24
US20170112840A1 (en) 2017-04-27
SG11201405006PA (en) 2014-10-30
US20150133424A1 (en) 2015-05-14
CU24335B1 (es) 2018-04-03
EA201491671A1 (ru) 2014-12-30
WO2013136254A1 (en) 2013-09-19
JP6093384B2 (ja) 2017-03-08
DK2834237T3 (en) 2018-08-27
IN2014MN01754A (es) 2015-07-03
ES2741896T3 (es) 2020-02-12
US9827247B2 (en) 2017-11-28
CN108383836A (zh) 2018-08-10
AP2014008009A0 (en) 2014-10-31
ES2684517T3 (es) 2018-10-03
KR20190100472A (ko) 2019-08-28
MA37405A1 (fr) 2016-03-31
CA2865167A1 (en) 2013-09-19
AU2017200493A1 (en) 2017-02-16
CU24272B1 (es) 2017-08-08
CN104203947A (zh) 2014-12-10
CR20140463A (es) 2014-11-28
HK1202538A1 (en) 2015-10-02
IL234560A (en) 2017-06-29
AP3834A (en) 2016-09-30
DOP2014000204A (es) 2015-02-15
PL2834237T3 (pl) 2018-11-30
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
AU2018202568A1 (en) 2018-05-10
KR20190073597A (ko) 2019-06-26
AU2017200493B2 (en) 2018-03-29
PH12014502041B1 (en) 2014-11-24
PH12014502040B1 (en) 2014-11-24
US20150299186A1 (en) 2015-10-22
HK1206020A1 (en) 2015-12-31
IL234559A (en) 2017-06-29
KR20140138910A (ko) 2014-12-04
CA2865164C (en) 2021-06-08
CR20140464A (es) 2014-11-28
US20170101408A1 (en) 2017-04-13
PE20141973A1 (es) 2014-12-12
US9969731B2 (en) 2018-05-15
AU2013234009B2 (en) 2016-10-27
NZ629432A (en) 2017-01-27
GEP201706671B (en) 2017-05-25
GT201400196A (es) 2017-09-28
EP2834236A1 (en) 2015-02-11
CU20140110A7 (es) 2014-11-27
WO2013136249A1 (en) 2013-09-19
AU2013234014A1 (en) 2014-09-25
EA029768B1 (ru) 2018-05-31
PE20141974A1 (es) 2014-12-12
JP6431770B2 (ja) 2018-11-28
CO7170131A2 (es) 2015-01-28
DK2834236T3 (da) 2019-08-26
CN104271577A (zh) 2015-01-07
MX366426B (es) 2019-07-08
BR112014022713A2 (es) 2017-06-20
MX355474B (es) 2018-04-16
NI201400108A (es) 2014-11-28
EP2834236B1 (en) 2019-05-22
PH12014502041A1 (en) 2014-11-24
SG11201405007QA (en) 2014-10-30
MA37400B1 (fr) 2019-11-29
KR20140138911A (ko) 2014-12-04
TR201811976T4 (tr) 2018-09-21
CN108383836B (zh) 2021-11-12
IN2014MN01755A (es) 2015-07-03
MX2014010928A (es) 2015-04-10
EA028232B1 (ru) 2017-10-31
GEP201706774B (en) 2017-11-27
MX355526B (es) 2018-04-20
UA114906C2 (uk) 2017-08-28
US20160331753A1 (en) 2016-11-17
CA2865164A1 (en) 2013-09-19
JP2015509975A (ja) 2015-04-02
AP2014008008A0 (en) 2014-10-31
US9573944B2 (en) 2017-02-21
AU2018202568B2 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
PH12014502040A1 (en) Heterocyclyl compounds
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
PH12014502605A1 (en) Uracyl spirooxetane nucleosides
MY175854A (en) Novel quinolone derivatives
PH12014502524B1 (en) Carboxylic acid compounds
IN2015DN01156A (es)
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
IN2014MN02598A (es)
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
IN2015DN01119A (es)
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
MX2016006337A (es) Compuestos heterociclicos novedosos.
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
IN2015DN02109A (es)
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors

Legal Events

Date Code Title Description
FG Grant or registration